163 related articles for article (PubMed ID: 31266785)
41. Intrinsic disorder may drive the interaction of PROS1 and MERTK in uveal melanoma.
Djulbegovic M; Taylor Gonzalez DJ; Antonietti M; Uversky VN; Shields CL; Karp CL
Int J Biol Macromol; 2023 Oct; 250():126027. PubMed ID: 37506796
[TBL] [Abstract][Full Text] [Related]
42. Mertk: An emerging target in cancer biology and immuno-oncology.
Lahey KC; Gadiyar V; Hill A; Desind S; Wang Z; Davra V; Patel R; Zaman A; Calianese D; Birge RB
Int Rev Cell Mol Biol; 2022; 368():35-59. PubMed ID: 35636929
[TBL] [Abstract][Full Text] [Related]
43. Differentiation of CD8+ T cells from tumor-invaded and tumor-free lymph nodes of melanoma patients: role of common gamma-chain cytokines.
Anichini A; Scarito A; Molla A; Parmiani G; Mortarini R
J Immunol; 2003 Aug; 171(4):2134-41. PubMed ID: 12902520
[TBL] [Abstract][Full Text] [Related]
44. 4-1BB-mediated expansion affords superior detection of in vivo primed effector memory CD8+ T cells from melanoma sentinel lymph nodes.
Sluijter BJ; van den Hout MF; Stam AG; Lougheed SM; Suhoski MM; van den Eertwegh AJ; van den Tol MP; van Leeuwen PA; Meijer S; Scheper RJ; June CH; de Gruijl TD; Santegoets SJ
Clin Immunol; 2010 Nov; 137(2):221-33. PubMed ID: 20708974
[TBL] [Abstract][Full Text] [Related]
45. The Inhibitory Signaling Receptor Protocadherin-18 Regulates Tumor-Infiltrating CD8
Frey AB
Cancer Immunol Res; 2017 Oct; 5(10):920-928. PubMed ID: 28874354
[TBL] [Abstract][Full Text] [Related]
46. Constitutive caspase activation and impaired death-inducing signaling complex formation in CD95-resistant, long-term activated, antigen-specific T cells.
Strauss G; Knape I; Melzner I; Debatin KM
J Immunol; 2003 Aug; 171(3):1172-82. PubMed ID: 12874203
[TBL] [Abstract][Full Text] [Related]
47. Mer Tyrosine Kinase Regulates Disseminated Prostate Cancer Cellular Dormancy.
Cackowski FC; Eber MR; Rhee J; Decker AM; Yumoto K; Berry JE; Lee E; Shiozawa Y; Jung Y; Aguirre-Ghiso JA; Taichman RS
J Cell Biochem; 2017 Apr; 118(4):891-902. PubMed ID: 27753136
[TBL] [Abstract][Full Text] [Related]
48. Cross-talk between 4-1BB and TLR1-TLR2 Signaling in CD8+ T Cells Regulates TLR2's Costimulatory Effects.
Joseph AM; Srivastava R; Zabaleta J; Davila E
Cancer Immunol Res; 2016 Aug; 4(8):708-16. PubMed ID: 27267778
[TBL] [Abstract][Full Text] [Related]
49. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
[TBL] [Abstract][Full Text] [Related]
50. Multiple sub-sets of CD4+ and CD8+ cytotoxic T-cell clones directed to autologous human melanoma identified by cytokine profiles.
Maccalli C; Mortarini R; Parmiani G; Anichini A
Int J Cancer; 1994 Apr; 57(1):56-62. PubMed ID: 7908659
[TBL] [Abstract][Full Text] [Related]
51. Distinct signal transduction in mouse CD4+ and CD8+ splenic T cells after CD28 receptor ligation.
Abe R; Vandenberghe P; Craighead N; Smoot DS; Lee KP; June CH
J Immunol; 1995 Feb; 154(3):985-97. PubMed ID: 7822814
[TBL] [Abstract][Full Text] [Related]
52. The Antitumor Effects of Vaccine-Activated CD8
Wu S; Zhu W; Peng Y; Wang L; Hong Y; Huang L; Dong D; Xie J; Merchen T; Kruse E; Guo ZS; Bartlett D; Fu N; He Y
Cancer Immunol Res; 2017 Oct; 5(10):908-919. PubMed ID: 28851693
[TBL] [Abstract][Full Text] [Related]
53. The Significance of Tumor Necrosis Factor Receptor Type II in CD8
Ye LL; Wei XS; Zhang M; Niu YR; Zhou Q
Front Immunol; 2018; 9():583. PubMed ID: 29623079
[TBL] [Abstract][Full Text] [Related]
54. Influence of T Cell Coinhibitory Molecules on CD8
Morris AB; Adams LE; Ford ML
Front Immunol; 2018; 9():1810. PubMed ID: 30135685
[TBL] [Abstract][Full Text] [Related]
55. Antigen-specific activation thresholds of CD8+ T cells are independent of IFN-I-mediated partial lymphocyte activation.
Wijesundara DK; Kumar S; Alsharifi M; Müllbacher A; Regner M
Int Immunol; 2010 Sep; 22(9):757-67. PubMed ID: 20682547
[TBL] [Abstract][Full Text] [Related]
56. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL
Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133
[TBL] [Abstract][Full Text] [Related]
57. Defective lymphokine production by most CD8+ and CD4+ tumor-specific T cell clones derived from human melanoma-infiltrating lymphocytes in response to autologous tumor cells in vitro.
Guilloux Y; Viret C; Gervois N; Le Dréan E; Pandolfino MC; Diez E; Jotereau F
Eur J Immunol; 1994 Sep; 24(9):1966-73. PubMed ID: 7522155
[TBL] [Abstract][Full Text] [Related]
58. CpG-A oligonucleotides induce a monocyte-derived dendritic cell-like phenotype that preferentially activates CD8 T cells.
Krug A; Rothenfusser S; Selinger S; Bock C; Kerkmann M; Battiany J; Sarris A; Giese T; Speiser D; Endres S; Hartmann G
J Immunol; 2003 Apr; 170(7):3468-77. PubMed ID: 12646607
[TBL] [Abstract][Full Text] [Related]
59. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
Roszkowski JJ; Lyons GE; Kast WM; Yee C; Van Besien K; Nishimura MI
Cancer Res; 2005 Feb; 65(4):1570-6. PubMed ID: 15735047
[TBL] [Abstract][Full Text] [Related]
60. Suppressor of cytokine signaling 1 regulates IL-15 receptor signaling in CD8+CD44high memory T lymphocytes.
Ilangumaran S; Ramanathan S; La Rose J; Poussier P; Rottapel R
J Immunol; 2003 Sep; 171(5):2435-45. PubMed ID: 12928391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
